Search research articles
Contact Us
Filters
Showing results (371-380 of 437) with videos related to
Page
of 44
Sort By:
Nature Communications
|
November 16, 2019
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
Giada Zurlo, Xijuan Liu, Mamoru Takada, et al.
Neurology. Genetics
|
December 16, 2022
Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES)
Massimo Pandolfo, Kathrin Reetz, Alejandra Darling, et al.
Neonatology
|
October 26, 2023
External Validation of a Multivariate Model for Targeted Surfactant Replacement
Francesco Raimondi, Pasquale Dolce, Claudio Veropalumbo, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2018
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
Joan Maurel, Santiago Sánchez-Cabús, Berta Laquente, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 4, 2011
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Carlos Alfaro, Jose L Perez-Gracia, Natalia Suarez, et al.
Biochemical and Biophysical Research Communications
|
May 1, 2016
Prolyl hydroxylase-1 regulates hepatocyte apoptosis in an NF-κB-dependent manner
Susan F Fitzpatrick, Zsolt Fábián, Bettina Schaible, et al.
Ebiomedicine
|
April 13, 2019
Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly
Miguel Chenlo, Iria A Rodriguez-Gomez, Ramon Serramito, et al.
The Lancet. Oncology
|
May 7, 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, et al.
Neonatology
|
July 6, 2022
Lung Ultrasound Scores Progress Differently in Extreme and Very Preterm Infants after Birth: A Multicentre Prospective Study
Almudena Alonso-Ojembarrena, Jon Montero-Gato, Rebeca Gregorio-Hernández, et al.
EMBO Molecular Medicine
|
June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.
Page
of 44
Search research articles
Search
Showing results (371-380 of 437) with videos related to
Sort By:
Page
of 44
Nature Communications
|
November 16, 2019
Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer
Giada Zurlo, Xijuan Liu, Mamoru Takada, et al.
Neurology. Genetics
|
December 16, 2022
Efficacy and Safety of Leriglitazone in Patients With Friedreich Ataxia: A Phase 2 Double-Blind, Randomized Controlled Trial (FRAMES)
Massimo Pandolfo, Kathrin Reetz, Alejandra Darling, et al.
Neonatology
|
October 26, 2023
External Validation of a Multivariate Model for Targeted Surfactant Replacement
Francesco Raimondi, Pasquale Dolce, Claudio Veropalumbo, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2018
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
Joan Maurel, Santiago Sánchez-Cabús, Berta Laquente, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
November 4, 2011
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Carlos Alfaro, Jose L Perez-Gracia, Natalia Suarez, et al.
Biochemical and Biophysical Research Communications
|
May 1, 2016
Prolyl hydroxylase-1 regulates hepatocyte apoptosis in an NF-κB-dependent manner
Susan F Fitzpatrick, Zsolt Fábián, Bettina Schaible, et al.
Ebiomedicine
|
April 13, 2019
Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly
Miguel Chenlo, Iria A Rodriguez-Gomez, Ramon Serramito, et al.
The Lancet. Oncology
|
May 7, 2021
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav, et al.
Neonatology
|
July 6, 2022
Lung Ultrasound Scores Progress Differently in Extreme and Very Preterm Infants after Birth: A Multicentre Prospective Study
Almudena Alonso-Ojembarrena, Jon Montero-Gato, Rebeca Gregorio-Hernández, et al.
EMBO Molecular Medicine
|
June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.
Page
of 44